-
Biotech Industry Intelligence6 months ago
Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data
Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data
-
Endpoints News6 months ago
More changes ahead for Takeda with new CEO set to take reins
Takeda’s multi-year restructuring will continue under incoming CEO Julie Kim. The company announced Wednesday that the board has approved “next steps” in its transformation that will...
-
STAT News – Biotech6 months agoSTAT+: Bhattacharya addresses CDC director role, works to bolster staff morale in first all-hands meeting
Centers for Disease Control and Prevention staff gathered Wednesday for what many hoped would be an announcement of the Trump administration’s choice for a new leader...
-
Endpoints News6 months ago
How Seaport is hedging against failure in Phase 2b depression study
Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial. The biotech is testing its drug, called SPT-300, in patients with major depressive disorder....
-
STAT News – Biotech6 months agoHeart failure is common. A quick MRI could improve diagnosis and guide treatment
Hearts need oxygen. Heart attacks are the most dramatic example of this hunger, when blocked coronary arteries starve muscles of the oxygen they need to keep...
-
BioPharma Dive – AI / Data6 months agoBeam posts positive data on base editing treatment for AATD
Updated data showed the biotech’s approach to the rare lung and liver condition helped restore functional protective proteins in a small study.
-
Endpoints News6 months ago
FDA approves Corcept’s Lifyorli for ovarian cancer months early
The FDA approved Corcept Therapeutics’ Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to...
-
AI, Machine Learning & Computational Biology6 months agoSTAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
The Food and Drug Administration on Wednesday approved a new medicine from Denali Therapeutics for a condition called Hunter syndrome, a notable decision by the agency...
-
AI, Machine Learning & Computational Biology6 months agoSTAT+: A 2023 health AI bet that seems to be paying off
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in...
-
GEN – Genetic Engineering & Biotechnology News6 months ago
The Three Pillars of Successful AI Deployments
Artificial intelligence and machine learning (AI/ML) are breakthrough tools in biopharmaceutical processing, but they are only as good as the dynamic processes they interact with. You...
Generic Drugs
China plans to transform $3M biotech sector into $522B powerhouse by 2030
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
